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Abstract
Background: Insecticide-treated nets (ITNs) are a proven intervention to reduce the burden of
malaria, yet there remains a debate as to the best method of ensuring they are universally utilized.
This study is a cost-effectiveness analysis of an intervention in Malawi that started in 1998, in
Blantyre district, before expanding nationwide. Over the 5-year period, 1.5 million ITNs were sold.
Methods: The costs were calculated retrospectively through analysis of expenditure data. Costs
and effects were measured as cost per treated-net year (cost/TNY) and cost per net distributed.
Results: The mean cost/TNY was calculated at $4.41, and the mean cost/ITN distributed at $2.63.
It also shows evidence of economies of scale, with the cost/TNY falling from $7.69 in year one
(72,196 ITN) to $3.44 in year five (720,577 ITN). Cost/ITN distributed dropped from $5.04 to
$1.92.
Conclusion: Combining targeting and social marketing has the potential of being both cost-
effective and capable of achieving high levels of coverage, and it is possible that increasing returns
to scale can be achieved.
Background
The cost-effectiveness of insecticide-treated nets in reduc-
ing morbidity and mortality in malaria endemic countries
has been proven time and again [1-3]. I It is considered to
be one of the most cost-effective ways of reducing the bur-
den of malaria, with an estimated cost per Disability
Adjusted Life Year (DALY) averted of under $50 [4]. How-
ever most studies have been undertaken along side trials,
and as such they equate to little more than measures of
cost-efficacy, leaving a need for better estimates of the true
cost-effectiveness of such programmes in practice. With
one of the main Roll Back Malaria goals being to achieve
at least 60% coverage of pregnant women and children
under five years of age with ITNs, evaluations of the cost-
effectiveness of different methods of financing and deliv-
ering nets on a large scale is desperately needed.
Differences in measures of cost-effectiveness in trials and
in interventions in practice are understandable, due to the
inevitable changes in returns to scale associated with the
scaling up of interventions [5,6], the operational difficul-
ties associated with programmes of this size [7,8] and the
constant returns to scale normally associated with primary
health care delivery systems. [9,10] A number of interven-
tions, that have been evaluated alongside trials, have been
shown to be far less effective and often more costly, once
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they have been scaled up and undertaken outside the con-
fines of the trial setting [11].
The debate as to the best way to achieve long-term shifts
in levels of ITN utilization in malaria endemic countries
has centered around the trade-off between the need for
immediate health impact and the need for long-term sus-
tainability of such a change in coverage. Those who advo-
cate the universal distribution of free nets have prioritized
the need for immediate results in terms of health gain,
whereas those who argue for the development of domestic
markets for ITNs wish to ensure the long-term sustainabil-
ity of utilization of ITNs. The Malawi model is a third way
that combines traditional, social marketing with heavily
subsidized highly-targeted distribution through the
nationwide network of public health facilities. Social mar-
keting has been defined as the application of 'commercial
marketing technologies to the analysis, planning, execu-
tion, and evaluation of programmes designed to influence
the voluntary behaviour of target audiences in order to
improve their personal welfare and that of their society'
[12]. In addition to this, the model has presented itself
with the challenge of achieving high coverage levels in a
relatively short period of time, while developing and sus-
taining a local market for ITNs which could sustain itself
into the future, when donor money reprioritizes or dries
up.
While there is a small but growing literature looking at the
application of social marketing techniques to ITN distri-
bution [2,13-17] the same cannot be said for economic
analyses. It has been said that social marketing has addi-
tional costs that free distribution nets do not, such as
advertising, branding, promotion and retailers' margins,
yet there has been only one published, cost-effectiveness
study of a social marketing project and that was deemed
to be cost-effective [2]. Currently the literature on the cost-
effectiveness of ITN distribution interventions is meas-
ured using only the immediate, directly relevant health
outcomes, and ignores any benefits from developing the
market for future accessibility. This is understandable, as
conventional forms of economic evaluation tend to over-
look issues of sustainability [18]. Nevertheless its value
comes in practicality; in the ability to make comparisons
between different methodologies with broadly similar
goals, and most fundamentally, in recognizing that the
resources available for health services are insufficient to
meet all the potential uses for them. This evaluation looks
at the cost-effectiveness of a specific social marketing ITN
intervention in terms of cost per ITN distributed and cost
per treated-net-year.
In 1998, USAID contracted Population Services Interna-
tional/ Malawi to design and implement a social market-
ing ITN programme in Blantyre district. The programme
strategy adopted has been published in detail elsewhere
[19]. In brief, the strategy involves segmenting the market
such that a more expensive blue conical net (with insecti-
cide treatment kit) is made available to consumers for $5–
6 through private sector outlets, targeting those who can
afford a commercially priced net. A subsidized green rec-
tangular net (with a kit) is made available to pregnant
women and children under 5 for $0.6, through public
health facilities. The nets were branded and heavily pro-
moted to the public through a range of mass media and
interpersonal communications channels.
Over the next three years the delivery of both the commer-
cially available net and the health facility model was
expanded nationwide, thanks to a collaborative effort
involving the Malawi Government, UNICEF, USAID and
DFID. By January 2003, ITNs were being delivered
through commercial outlets and public health facilities in
all 27 districts of the country. To further improve access to
ITNs, in 2003, unbranded green rectangular nets (with a
kit) were delivered via community-based groups at the
subsidised price of $1.2. During the latter 12 month
period reported here (October 2002 – September 2003), a
total of 942,000 nets were sold of which 8% were blue
conical nets, 16% were unbranded green rectangular nets
delivered via community-based channels and 76% were
green rectangular nets delivered through public health
facilities. At the time of writing, the programme continues
to sell about 100,000 ITNs per month nationwide with
roughly the same proportion of each type of net.
Methods
The costs were taken from financial expenditure data col-
lected over the course of the first five years of the pro-
gramme. As the study was retrospective, no research costs
are included. The costs relate to Blantyre District only in
year one, and nationwide from year two.
Costs were broken down into capital costs, which were
annualized and discounted across their life span, and
recurrent or programme costs. The latter were broken
down into direct costs associated with the ITN pro-
gramme, and shared costs which were apportioned using
one of three indicators. The first was budget headings, the
second was total volume of product and the third was
total sales calls by agents. An appropriate apportionment
method was chosen for each type of expenditure, for
example, in terms of apportioning warehouse rental,
product volume was used, as ITNs take up much more
space than condoms or sachets of oral rehydration salts,
which are also delivered by PSI/Malawi. Whereas, with
cost of sales commissions, the number of sales calls was
used, which better represented the relative effort of the
sales agents.Malaria Journal 2005, 4:22 http://www.malariajournal.com/content/4/1/22
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Capital items were annualized over assumed life spans,
taken directly from the KINET study 2 so that comparison
with other studies, the main aim of this study, could be
more transparent. The brand was estimated at seven years;
billboards and vehicles were eight years, and computers,
furniture and the bed-nets themselves were five years. The
discount rate used was 3%, and costs were measured in a
combination of local currency (Malawi Kwacha) and in
US dollars, depending on whether the resources were pur-
chased or paid locally or overseas. All costs were then
translated into US dollars on the MK-US$ exchange rate
for July 1st of that year.
Results
Costs
The financial cost of the programme, shown in Table 1,
over the first five years was just over $6 million, with an
economic cost from 1998–2003 of just over $3,500,000.
In this time, a little under 1.5 million ITNs and 300,000
re-treatment kits were sold. Table 2 shows the breakdown
of the costs by line item, with set-up costs making up 3%,
capital costs making up 57% and recurrent costs making
up 40%. The biggest cost was that of the nets and the
insecticide, which made up 60% of total costs, followed
by staff, which made up 10%. Overhead costs, including
local overheads, and the cost of technical support from
the PSI/Washington office was also 10%.
Consequences
As this is a retrospective evaluation of an ongoing working
programme, rather than a trial, no health impact data was
collected, and so the focus is on process outcomes, includ-
ing the number of nets distributed and the number of
treated net years. The latter measure comes from previous
literature on CEA of ITNs [2] and does not require direct
translation into health benefits. This allows the results
from this study to be compared with other studies. The
choice of cost per treated-net-year (TNY) is conservative,
as it assumes zero benefit from an untreated net and insec-
ticide treatment is assumed to last 6 months. The discus-
Table 1: Financial and economic costs of the programme from 1999–2003 (1999 prices).
Total financial cost (US $) Total economic cost (US $)
Brand creation / market research 146,801 107,085
Capital costs
Vehicles 157,552 50,228
Equipment & furniture 15,468 15,468
ITNs 4,478,365 2,147,400
Subtotal 4,651,385 2,213,096
Recurrent costs
Insecticide 191,555 191,555
Staff 357,204 357,204
Fuel/maintenance 339,346 339,346
Office /warehouse rental 45,672 45,672
Advertising & Promotion 272,646 272,646
Supplies/overheads 351,682 351,682
Subtotal 1,558,104 1,558,104
Total cost 6,356,290 3, 878,287
ITNS distributed 1,471,941
Retreatments distributed 287,079
Treated net years 879,510
Cost per net distributed 2.63
Cost per treated net year 4.41Malaria Journal 2005, 4:22 http://www.malariajournal.com/content/4/1/22
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sion draws from the literature on the efficacy of ITNs to
estimate the likely health impact and more recognizable
measures of cost-effectiveness.
Cost and effectiveness
The average economic cost per net delivered and the aver-
age cost per treated-net-year, over the five years, are $2.63
and $4.41 respectively. This compares favourably to other
studies where estimates of $8 and $4 [2,3] have been
shown. The interesting aspect of this study is the gains
from cost savings from producing at higher levels, or what
is often termed scale efficiency savings (SES) that are
made, as shown in Table 2, where the cost per treated-net-
year drops from $7.69 to $3.44 as throughput rises from
72,196 to 720,577 ITNs.
Discussion
It is vital for policy-makers to have information on the
costs and effects of scaling up malaria interventions,
including the provision of ITNs. Recent work in this area
has undoubtedly helped to begin addressing this issue.
For example, the work by the Commission for Macroeco-
nomics and Health has provided preliminary estimates of
costs of scaling up 5 malaria-related interventions includ-
ing diagnosis and treatment for over-fives, chemoprophy-
laxis or presumptive treatment for pregnant women,
provision of insecticide-treated nets and residual house-
hold spraying for malaria prevention [22]. A number of
countries are also experimenting with scaling up of inter-
ventions designed to improve the home management of
malaria. Lessons learnt in Ghana, Uganda, Nigeria,
Burkina Faso, Zambia and Kenya are now being shared
[23]. While there is no doubt that researchers are paying
more attention to issues surrounding the costs and effects
of scaling up malaria interventions, there is still a way to
go, especially with regard to the delivery of ITNs. In partic-
ular, the costs of scaling up ITNs are currently restricted to
a relatively small number of studies based on the evalua-
tion of trials or research studies that are often of limited
scale. These studies also fail to account for the inevitable
growth of scaling up over time that is present in imple-
mentation of many public health interventions. The pur-
pose of this study is to start to address these gaps by
incorporating ongoing fieldwork into the cost-effective-
ness debate around the delivery of ITNs.
Scaling up of ITN delivery
One of the key findings of this study is that there are con-
siderable scale-efficiency savings to be made. Table 3
shows us the scale efficiency savings (SES) over the five
Table 2: Annual costs and cost-effectiveness ratios of the programme 1999–2003 (1999 prices)
1999 2000 2001 2002 2003 Average (%)
Brand creation 20,972 21,161 21,279 21,687 21,986 21,417 3%
Capital costs
Vehicles 4,056 6,144 8,381 14,595 17,053 10,046 1%
Equipment & furniture 1,903 3,288 4,208 2,848 3,221 3,094 0%
ITNs 77,394 202,893 348,829 586,770 931,515 429,480 55%
Subtotal 83,353 212,325 361,418 604,213 951,789 442,619 57%
Recurrent costs
Insecticide 16,753 34,335 38,808 58,076 43,582 38,311 4%
Staff 81,496 90,572 54,058 64,104 66,974 71,441 10%
Fuel/maintenance 37,346 67,105 44,115 94,223 96,558 67,869 9%
Office /warehouse rental 806 6,380 10,204 14,202 14,080 9,134 1%
Advertising & Promotion 83,960 71,846 48,149 27,603 41,087 54,529 7%
Supplies/overheads 38,954 42,492 42,905 82,322 145,008 70,336 10%
Subtotal 259,315 312,731 238,240 340,531 407,288 311,621 40%
ITNS distributed 72,196 131,881 174,376 372,911 720,577 294,388
Retreatments distributed 22,337 46,731 54,103 81,824 82,084 57,416
Treated-net-years 47,267 89,306 114,240 227,368 401,331 175,902
Total cost 363,640 546,217 620,937 966,431 1,381,063 775,657 100%
Cost per net distributed 5.04 4.14 3.56 2.59 1.92 2.63
Cost per treated-net-year 7.69 6.12 5.44 4.25 3.44 4.41Malaria Journal 2005, 4:22 http://www.malariajournal.com/content/4/1/22
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years and relates them to increases in throughput of ITNs.
SES has been separated into two components, the 'pro-
curement SES' and the 'distribution SES'. This allows us to
see to what extent the SES are a component of this partic-
ular method of distribution and what part of the SES is
due primarily to the greater bargaining power of scale. As
can be seen from this data, approximately half of the rela-
tive efficiency savings over time are due to lowering prod-
uct or procurement costs.
It could be estimated that these SES could have been
enjoyed by any of the alternative methods of distribution,
whereas the distribution SES is probably more closely
related to the specifics of the distribution method
employed, although this is purely speculation, as there is
no comparator. What we can say is that health systems,
particularly public sector health systems are not renowned
for their economies of scale or for falling marginal costs,
and that recent studies looking at opening public services
up to private competition has tended to increase cost-effi-
ciency and returns to scale [20]. One thing is certain, there
is a growing belief that the reliance on an assumption of
constant returns to scale is limiting the value and practi-
cality of cost-effectiveness studies to policy makers [5,21].
Currently, despite the evidence of the relative cost-effec-
tiveness of ITNs and the goals and the political commit-
ment of the RBM partners to increase coverage throughout
sub-Saharan Africa beyond the 60% mark, there has not
been the speed of progress in scaling up of this interven-
tion that has been required. A recent study by the CDC
and UNICEF looked at changes in ITN and bed-net usage
in Malawi as a whole between 2000 and 2003 [22].
Households of at least one net have risen from 12% to
43%. In target groups, 35% of children under 5 slept
under a net the previous night, up from 8% and similarly,
32% of pregnant women slept under a net the previous
night, up from just 8% three years previously. These are
significant changes in a relatively short period of time.
At this time, this is partly due to a lack of financial com-
mitment which is, in turn, due to a lack of a consensus on:
a) how best to undertake this scale up; and b) how much
it is likely to cost. The first of these two cannot be
answered unless the desired output, be it pure short-term
health gain, long-term development of a sustainable net
culture, or both, is clarified. The second needs to consider
the fact that economies-of-scale may exist. If estimates of
the cost of achieving certain targets are based on cost-
effectiveness data from small scale trials, and modeled at
constant returns to scale there is a chance this could dras-
tically overestimate the true cost, if the evidence presented
here on returns to scale is not an anomaly. Without more
evaluations of programmes at scale to compare, this can
only be speculation.
Conclusion
The efficacy of insecticide-treated nets for reducing the
burden of malaria in sub-Saharan Africa has been repeat-
edly proven and the debate in this field should, and to
Table 3: Breakdown of total scale efficiency savings into 'procurement' and 'distribution' costs
Financial unit costs 1999 2000 2001 2002 2003 Totals/Average
ITN unit cost 5.36 4.67 4.01 3.05 2.27 3.04
Retreatment pack u/c 0.75 0.75 0.75 0.75 0.57 0.70
ITNs 72,196 131,881 174,376 372,911 720,577 1,471,941
Retreatment packs 22,337 46,731 54,103 81,824 82,084 287,079
Treated net years 47,267 89,306 114,240 227,368 401,331 879,510
Output growth (actual) 42,040 24,934 113,128 173,963 478,180
Output growth (%) 89% 28% 99% 77% 73%
Procurement U/C 5.36 4.67 4.01 3.05 2.27
U/C savings 0.69 0.66 0.96 0.78 3.09
SES 13% 14% 24% 26% 58%
Distribution U/C 3.73 2.33 1.32 0.85 0.56
U/C savings 1.40 1.01 0.47 0.30 3.18
SES 37% 43% 36% 35% 85%
Total U/C 9.09 7.00 5.33 3.90 2.83
Savings U/C 2.09 1.67 1.43 1.08 6.27
SES 23% 24% 27% 28% 69%Malaria Journal 2005, 4:22 http://www.malariajournal.com/content/4/1/22
Page 6 of 6
(page number not for citation purposes)
some extent has, moved beyond marginal value to one of
measuring marginal productivity. The goal for economists
and policymakers is to determine the method, or combi-
nations of methods, that can ensure the best way of
achieving a sustainable high-level of utilization of this
product in communities where the benefits are highest.
It is more than likely that with the dual goals of health
impact through high coverage levels, and long-term sus-
tainability of the supply of ITNs in those same countries,
that a strategy which involves a combination of different
methods of distribution will be required. This paper sug-
gests that a combination of standard social marketing
techniques, combined with targeting vulnerable groups
with highly subsidized ITNs through both the commercial
and formal health care sectors, could achieve relatively
high-levels of coverage in both urban and rural areas and
in vulnerable groups over time with proper investment.
In addition, contrary to the weight of evidence on scaling
up of public health interventions, and of primary health
care in general, it may be possible to achieve these high
levels of ITN distribution and rapid increases in coverage
while keeping unit costs down and achieving increasing
returns to scale. To justify such a conclusion, and to com-
pare and contrast with other hybrid methods of ITN deliv-
ery, economic evaluations of large-scale programmes
need to be carried out.
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